Business
Medical Marijuana, Inc. Major Investment Company AXIM® Biotechnologies, Inc.'s Cannabinoid Oral Care Products Registered For Use In Clinical Trials Through Australian Healthcare Partner
Medical Marijuana, Inc. Major Investment Company AXIM® Biotechnologies, Inc.'s Cannabinoid Oral Care Products Registered For Use In Clinical Trials Through Australian Healthcare Partner.
About this update from Axim Biotechnologies, Inc.
[{"type":"text","content":"\n\n\n\nMedical Marijuana, Inc. Major Investment Company AXIM® Biotechnologies, Inc.'s Cannabinoid Oral Care Products Registered For Use In Clinical Trials Through Australian Healthcare Partner\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nMedical Marijuana, Inc. Major Investment Company AXIM® Biotechnologies, Inc.'s Cannabinoid Oral Care Products Registered For Use In Clinical Trials Through Australian Healthcare Partner\nPR Newswire\nNEW YORK, June 26, 2019\n\n\n\nNEW YORK, June 26, 2019 /PRNewswire/ -- Medical Marijuana, Inc. (OTC:MJNA) (the \"Company\"), the first-ever publicly traded cannabis company in the United States that launched the world's first-ever cannabis-derived nutraceutical products, brands and supply chain, announced today that products from the Company's major investment company AXIM® Biotechnologies, Inc. (OTC: AXIM) (\"AXIM® Biotech,\" \"AXIM\"), a world leader in cannabinoid research and development, were included in registration for clinical trials through the Australian and New Zealand Clinical Trial Registry. The products will be used during the trial are part of AXIM's patented oral care line and include its cannabinoid-based mouthwash and toothpaste.\n\"There is no doubt that the CBD industry, as with any scientific field, could benefit greatly from additional research. We are proud to take part in this clinical trial with AXIM's patented oral care products to further prove the efficacy of the company's products,\" said Medical Marijuana, Inc. CEO Dr. Stuart Titus.\nThe trials were registered by Impression Healthcare Limited (\"Impression\"), Australia's largest home dental impression company, which plans to conduct a phase 2a randomized controlled clinical trial to evaluate the clinical safety and efficacy of the products on 40 people suffering from gingivitis and gum disease. Trial participants will use the toothpaste and mouthwash three times a day over 30 days and will be monitored for gum inflammation and overall gum health.\nAccording to Impression, about 20 percent of the Australian population suffe...